Biosimilar drugs are manufactured similarly to biologic drugs. Like biologics, they are derived from living cells (human, animal, or bacterial) in a lab setting. Many people think biosimilars are ...

eResearchTechnology GmbH, ICON plc, IQVIA Holdings Inc ... Small-molecule drugs, biologics, biosimilars, and large-molecule drugs are all under development, with raw material suppliers and ...

Biosimilars, potentially lower-cost versions of biologics, may improve access to more affordable yet comparably effective treatments. Encouragingly, China launched its abbreviated biosimilar pathway ...

Biocon Biologics has secured USFDA approval to launch the biosimilar of Janssen's Stelara by February 2025, targeting autoimmune conditions like Crohn's disease and plaque psoriasis. Despite ...

Yesintek, a Stelara biosimilar, received FDA approval for IBD, plaque psoriasis, and psoriatic arthritis, with a launch expected in late 2025. Clinical trials confirmed Yesintek's equivalence to ...

Biocon Biologics Ltd. has received US Food and Drug Administration approval for Yesintek, a biosimilar for Johnson & Johnson's reference product, Stelara. This approval marks a major breakthrough for ...

In November 2024, Skyrizi surpassed Humira as AbbVie's top seller; calls for PBM transparency and biosimilar access reforms grew; Celltrion expanded its portfolio; and Global Biosimilars Week focused ...

Modern biosimilar discovery projects involve vast volumes of data, with massive datasets that are often difficult to unify, navigate, and process Modern drug discovery and biosimilar development ...

Regulatory policies influence the availability of affordable biosimilars, with varying impacts across different jurisdictions. Policies promoting product-specific guidance, extrapolation, shorter ...

Biosimilars demonstrate comparable drug survival and safety with adalimumab among new users, but patients switching from Humira (the originator product) to biosimilars had a 35% higher ...